Navigation Links
Horizon Therapeutics Completes Enrollment in Phase 3 Trials for Lead Product Candidate HZT-501
Date:2/11/2008

- Over 1,500 U.S. patients enrolled in study examining potential new

'GI-friendly' treatment for mild to moderate pain -

- Clinical results expected in second half of 2008 -

PALO ALTO, Calif., Feb. 11 /PRNewswire/ -- Horizon Therapeutics, Inc., a privately held biopharmaceutical company, today announced that it is closing enrollment in its two phase 3 trials HZ-CA-301 and HZ-CA-303 for its lead product candidate HZT-501, an investigational prescription NSAID (non-steroidal anti-inflammatory drug) designed to be "GI-friendly".

"We enrolled over fifteen hundred patients in less than a year, which was well ahead of our projections," said George F. Tidmarsh, M.D., Ph.D., co-founder and chief executive officer of Horizon Therapeutics. "We look forward to receiving the complete set of clinical results and safety data to review this Fall."

The Phase 3 program is comprised of two trials involving a total of 1,500 patients with mild-to-moderate pain, including patients with osteoarthritis. Horizon Protocol HZ-CA-301 and HZ-CA-303 are evaluating the efficacy and safety of HZT-501 with a primary endpoint of reduction in the risk of development of ibuprofen-associated upper gastrointestinal (gastric and/or duodenal) ulcers in patients who require the use of ibuprofen.

The clinical trials are multi-center, randomized, controlled, and blinded for up to 24 weeks of treatment, followed by a 4 week safety evaluation period. The studies are being conducted in the United States.

"The Horizon studies are among the largest endoscopic trials ever conducted regarding NSAID-induced gastrointestinal ulcers," said Loren Laine M.D., professor of medicine in the Division of Gastrointestinal and Liver Diseases, University of Southern California. "The results should provide precise estimates of the potential benefit of HZT-501 in decreasing NSAID-associated ulcers."

In addition, a phase 3 follow-on safety study HZ-CA-30
'/>"/>

SOURCE Horizon Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Horizon Therapeutics Initiates Long-Term Phase 3 Safety Study for Lead Product Candidate HZT-501
2. GlaxoSmithKline and Theravance Announce Start of Large Phase 2B ICS and LABA Studies for Asthma in the Horizon Program
3. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
6. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
7. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
8. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014  A novel wearable injector slightly larger than an Oreo ... to self-inject prescription drugs in the large doses required to ... autoimmune deficiencies, and genetic disorders.  An emerging ... 2018, according to analysts.   Many of these drugs will require ...
(Date:1/14/2014)... Dynamic Healthcare Services, Inc. ("DHS"), a portfolio company of GMH ... Medical Equipment, Inc. ("Progressive") of Clarion, PA ... were not disclosed. Progressive is a full ... of sleep, mobility, and respiratory products to customers in the ...
(Date:1/14/2014)... , Jan. 14, 2014   Oligomerix, Inc. , a privately ... for Alzheimer,s disease (AD) and related neurodegenerative disorders, announced ... Valhalla, NY as of January 15, ... at New York Medical College. Oligomerix, which ...
Breaking Medicine Technology:Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... the medical device industry gathers at Sales and Marketing Excellence 2010 ... device companies a solution to promote and sell in this highly regulated ... Maureen Shaffer ... "Sales-Friendly Compliant Content Communication: How to Score Wins for Sales, Marketing, and ...
... Georgia , May 20, 2010 , ... - Critical Care Pharmacology Course Promotes Patient ... ... than 1,300 healthcare organizations,has partnered with the American Association of Critical-Care Nurses (AACN) ...
Cached Medicine Technology:Prolifiq Offers Best Practices Solution for Selling Medical Devices in Tough Regulatory Environment 2Prolifiq Offers Best Practices Solution for Selling Medical Devices in Tough Regulatory Environment 3Elsevier/MC Strategies Partners with American Association of Critical-Care Nurses to Launch Interactive, Online Pharmacology Course 2Elsevier/MC Strategies Partners with American Association of Critical-Care Nurses to Launch Interactive, Online Pharmacology Course 3Elsevier/MC Strategies Partners with American Association of Critical-Care Nurses to Launch Interactive, Online Pharmacology Course 4Elsevier/MC Strategies Partners with American Association of Critical-Care Nurses to Launch Interactive, Online Pharmacology Course 5Elsevier/MC Strategies Partners with American Association of Critical-Care Nurses to Launch Interactive, Online Pharmacology Course 6Elsevier/MC Strategies Partners with American Association of Critical-Care Nurses to Launch Interactive, Online Pharmacology Course 7
(Date:4/23/2014)... the United States, it may come as a surprise that ... food due to lack of money or other financial resources. ... University of Illinois using data from the National Health and ... dealing with hunger are also facing negative health and nutrition ... age 60 faced the threat of hungerthat translates to 4.8 ...
(Date:4/23/2014)... journal Oncotarget , explored tumour heterogeneity ... own DNA signatures within the same cancer. Such ... targeted treatment strategies. , Firstly they confirmed the ... the KRAS or BRAF mutation. Secondly, they found ... mutation have that specific mutation present uniformly throughout ...
(Date:4/22/2014)... visited the New Jersey Institute of Technology (NJIT) ... for the launch of the New Jersey Innovation ... new model for business innovation through the leveraging ... investment. U.S. Senator Cory Booker, Panasonic Corp. of ... Jersey Lieutenant Governor Kim Guadagno, New Jersey Secretary ...
(Date:4/22/2014)... 15 percent of all lung cancers are small ... often develop resistance to chemotherapy. However, researchers at ... new insights into the mechanisms leading to this ... , Chemotherapies work primarily by mediating B-cell lymphoma ... regulating cell death. Depending on their function, this ...
(Date:4/22/2014)... NY, April 22, 2014Hemoglobin A1c is the standard measurement ... diabetes. Blood levels of A1c are typically measured every ... developed a data-based model that accurately estimates A1c using ... Diabetes Technology & Therapeutics ( DTT ), a ... article is available free on the DTT ...
Breaking Medicine News(10 mins):Health News:More Americans in their golden years are going hungry 2Health News:Non-uniform genetic mutations identified in lung cancers could lead to targeted treatment 2Health News:Government and industry leaders herald launch of NJIT's New Jersey Innovation Institute 2Health News:Scientists pinpoint protein that could improve small cell lung cancer therapies 2
... HAVEN, Conn., May 29 ... today announced that an analysis of clinical data of ... myeloid leukemia (AML) would be presented in a poster ... Annual Meeting in Orlando, Florida.The poster (Abstract #7050) entitled ...
... Minimally Invasive Spine Surgery Provides Better Diagnosis and Treatment ... Kenneth L. Reed, M.D. performed the first revolutionary ... to treat acute and chronic back pain ... physicians are the only doctors performing the procedure in ...
... available for incontinence nowadays, an effective and easy solution ... incontinence. The main roadblock to that solution might just ... his condition. Dr. Peter Muench of Delaware Urologic Associates ... advises patients that full disclosure is the best policy ...
... Scottish Widows paid over £28m in critical illness cover claims between November ... due to non-disclosure, The three main reasons for claims - cancer, heart ... ... Scottish Widows, one of the most trusted brands in life insurance ...
... in a Series of Community Discussions on Improving Access ... Teva Pharmaceuticals USA, the leading generic pharmaceutical company, ... roundtables as part of their Year of Affordable Healthcare ... at the YMCA San Francisco, aimed at raising awareness ...
... balloon also floated by President Clinton in 1993 to pay ... comes to finding a way to finance government-run health care, ... balloon echoing that of President Bill Clinton in 1993.The Obama ... spokesman for Obama Budget Director Peter Orszag, who was quoted ...
Cached Medicine News:Health News:Vion Pharmaceuticals to Present Data on Onrigin(TM)at the ASCO(R) Annual Meeting 2Health News:Vion Pharmaceuticals to Present Data on Onrigin(TM)at the ASCO(R) Annual Meeting 3Health News:Kenneth L. Reed, M.D. Performs First State of the Art AccuraScope(TM) Procedure in Dallas 2Health News:Delaware Urologic Associate's, Dr. Peter J. Muench, Presents Advances in Incontinence Treatment with a New Perspective and Outlook 2Health News:Delaware Urologic Associate's, Dr. Peter J. Muench, Presents Advances in Incontinence Treatment with a New Perspective and Outlook 3Health News:Delaware Urologic Associate's, Dr. Peter J. Muench, Presents Advances in Incontinence Treatment with a New Perspective and Outlook 4Health News:Scottish Widows Releases Critical Illness Cover Claims Figures 2Health News:The Year of Affordable Healthcare Brings Together San Francisco Community Groups to Tackle Healthcare Crisis 2Health News:ATR: Obama's VAT Trial Balloon Dusts Off Bill Clinton's 1993 Playbook 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: